Methodology for determining major constituents of ayahuasca and their metabolites in blood

Biomedical Chromatography

Volumn 26, Issue 3, 2012, Pages 301-313

  McIlhenny, Ethan H ^a   Riba, Jordi ^b,c   Barbanoj, Manel J ^b,c   Strassman, Rick ^d,e   Barker, Steven A ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e Cottonwood Research Foundation ^*  (United States)

Author keywords

Ayahuasca; Blood; Dimethyltryptamine; Harmala alkaloids; Metabolism

Indexed keywords

ALKALOIDS; BIOMOLECULES; BLOOD; CLINICAL RESEARCH; ELECTROSPRAY IONIZATION; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION OF GASES; MASS SPECTROMETRY; MEDICAL APPLICATIONS;

AYAHUASCUM; BLOOD; CLINICAL RESEARCH; COMPREHENSIVE METHOD; DIMETHYLTRYPTAMINE; FLUORESCENCE DETECTION; HARMALUM ALKALOID; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVE METHOD; ULTRAVIOLET FLUORESCENCE;

METABOLITES;

5 METHOXY N,N DIMETHYLTRYPTAMINE; 7 HYDROXY TETRAHYDROHARMINE; ALKALOID; AYAHUASCA EXTRACT; DRUG METABOLITE; HARMALINE; HARMINE; HARMOL; INDOLEACETIC ACID; N METHYLTRYPTAMINE; N,N DIMETHYLKYNURAMINE; N,N DIMETHYLTRYPTAMINE; NITROGEN; PHOSPHORUS; PSYCHOTROPIC AGENT; TETRAHYDROHARMINE; UNCLASSIFIED DRUG;

ARTICLE; AYAHUASCA; CASE REPORT; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; ELECTROSPRAY; FILTRATION; FLUORESCENCE ANALYSIS; FOOD INTAKE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MEDICINAL PLANT; METABOLITE; PRECIPITATION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TEA; ULTRAVIOLET SPECTROSCOPY;

BANISTERIOPSIS CAAPI;

EID: 80755123519     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1657     Document Type: Article

References (37)

1. Andritzky W. Sociopsychotherapeutic functions of ayahuasca healing in Amazonia. Journal of Psychoactive Drugs 1989; 21: 77-89.
2. Barker SA, Monti JA and Christian ST. Metabolism of the hallucinogen N, N-dimethyltryptamine in rat brain homogenates. Biochemical Pharmacology 1980; 29: 1049-1057.
3. Barker SA, Monti JA and Christian ST. N, N-Dimethyltryptamine: an endogenous hallucinogen. International Review of Neurobiology 1981; 22: 83-110.
4. Callaway JC. Various alkaloid profiles in decoctions of Banisteriopsis caapi. Journal of Psychoactive Drugs 2005; 37: 1-5.
5. Callaway JC, Airaksinen MM, McKenna DJ, Brito GS and Grob CS. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology 1994; 116: 385-387.
6. Callaway JC, Raymon LP, Hearn WL, McKenna DJ, Grob CS, Brito GS and Mash DC. Quantitation of N, N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. Journal of Analytical Toxicology 1996; 20: 492-497.
7. Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, Andrade EN, Andrade EO and Mash DC. Pharmacokinetics of Hoasca alkaloids in healthy humans. Journal of Ethnopharmacology 1999; 65: 243-256.
8. Callaway JC, Brito GS and Neves ES. Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis. Journal of Psychoactive Drugs 2005; 37: 145-150.
9. Chambers E, Wagrowski-Diehl DM, Lu Z and Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. Journal of Chromatography B 2007; 852: 22-34.
10. Fábregas JM, González D, Fondevila S, Cutchet M, Fernández X, Barbosa PC, Alcázar-Córcoles MÁ, Barbanoj MJ, Riba J and Bouso JC. Assessment of addiction severity among ritual users of ayahuasca. Drug and Alcohol Dependence 2010; 111: 257-261.
11. Hallikainen T, Saito HM, Lachman J, Volavka T, Pohjalainen OP, Ryynanen J, Kauhanenm J, Syvalahti E, Hietala J and Tiihonen J. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior. Molecular Psychiatry 1999; 4: 385-388.
12. Hryhorczuk LM, Rainey JM, Frohman C and Novak E. A new metabolic pathway for N, N-dimethyltryptamine. Biological Psychiatry 1986; 21: 84-93.
13. Kim H, Sablin SO and Ramsay RR. Inhibition of monoamine oxidase A by beta-carboline derivatives. Archives of Biochemistry and Biophysics 1997; 337: 137-142.
14. Mabit J, Giove R and Vega J. In Yearbook of Cross-cultural Medicine and Psychotherapy, Winkelman M and Andritzky W (eds). VMB Press: Berlin, 1996; 257.
15. Mantere T, Tupala E, Hall H, Sarkioja T, Rasanen P, Bergstorm K, Callaway JC and Tiihonen J. Serotonin transporter distribution and density in the cerebral cortex of alcoholic and nonalcoholic comparison subjects: a whole-hemisphere autoradiography study. American Journal of Psychiatry 2002; 159: 599-606.
16. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030.
17. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. Journal of Chromatography B 2006; 830: 293-300.
18. McIlhenny EH, Pipkin KE, Standish LJ, Wechkin HA, Strassman RJ and Barker SA. Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography-electrospray ionization-tandem mass spectrometry. Journal of Chromatography A 2009; 1216: 8960-8968.
19. McIlhenny EH, Riba J, Barbanoj MJ, Strassman R and Barker SA. Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. Biomedical Chromatography 2010; doi: 10.1002/bmc.1551.
20. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology & Therapeutics 2004; 102: 111-129.
21. McKenna DJ and Towers GHN. Biochemistry and pharmacology of tryptamines and beta-carbolines: a minireview. Journal of Psychoactive Drugs 1984; 16: 347-358.
22. McKenna DJ, Towers GHN and Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. Journal of Ethnopharmacology 1984; 10: 195-223.
23. Moura DJ, Richter MF, Boeira JB, Henriques JAP and Saffi J. Antioxidant properties of β-carboline alkaloids are related to their antimutagenic and antigenotoxic activities. Mutagenesis 2007; 22: 293-302.
24. Pires APS, De Oliveira CDR, Moura S, Dorr FA, Silva WAE and Yonamine M. Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage. Phytochemical Analysis 2009; 20: 149-153.
25. Riba J. Human pharmacology of ayahuasca. Doctoral Thesis, Universitat Autonoma de Barcelona, 2003.
26. Riba J and Barbanoj MJ. Bringing ayahuasca to the clinical research laboratory. Journal of Psychoactive Drugs 2005; 37: 219-230.
27. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC and Barbanoj MJ. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berlin) 2001; 154: 85-95.
28. Riba J, Valle M, Urbano G, Yritia M, Morte A and Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. The Journal of Pharmacology and Experimental Therapeutics 2003; 306: 73-83.
29. Rivier L and Lindgren JE. 'Ayahuasca, ' the South American hallucinogenic drink: an ethnobotanical and chemical investigation. Economic Botany 1972; 26: 101-129.
30. Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V and Cruz APM. Effects of ayhuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. Journal of Ethnopharmacology 2007; 112: 507-513.
31. Sitaram BR and McLeod WR. Observations on the metabolism of the psychotomimetic indolealkylamines: Implications for future clinical studies. Biological Psychiatry 1990; 28: 841-848.
32. Sitaram BR, Lockett L, Blackman GL and McLeod WR. Urinary excretion of 5-methoxy-N, N-dimethyltryptamine, N, N-dimethyltryptamine and their N-oxides in the rat. Biochemical Pharmacology 1987a; 36: 2235-2237.
33. Sitaram BR, Lockett L, Talomsin R, Blackman GL and McLeod WR. In vivo metabolism of 5-methoxy-N, N-dimethyltryptamine and N, N-dimethyltryptamine in the rat. Biochemical Pharmacology 1987b; 36: 1509-1512.
34. Sitaram BR, Talomsin R, Blackman GL and McLeod WR. Study of metabolism of psychotomimetic indolealkylamines by rat tissue extracts using liquid chromatography. Biochemical Pharmacology 1987c; 36: 1503-1508.
35. Taylor PJ. Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometery. Clinical Biochemistry 2005; 38: 328-334.
36. Tiihonen J, Kiukka JT, Bergstorm KA, Karhu J, Viinamaki H, Lehtonen J, Hallikainen T, Yang J and Hakola P. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behavior. European Journal of Nuclear Medicine 1997; 24: 1253-1260.
37. Yritia M, Riba J, Ortuno J, Ramirez A, Castillo A, Alfaro Y, De La Torre R and Barbanoj MJ. Determination of N, N-dimethyltryptamine and beta carboline alkaloids in human plasma following oral administration of Ayahuasca. Journal of Chromatography B 2002; 779: 271-281.